case_images: PMC3715974_01
case_images: (a and b) Baseline PET-CT showing bilateral groin lymphadenopathy with scrotal edema. (c and d) Post 12 weeks resolution of right groin lymphadenopathy with persistent disease on left side. (e and f) Showing resolution of lower inguinal lymphadenopathy with persistent scrotal edema-post 12 weeks of therapy
case_images: IJMPO-34-24-g001.jpg
case_images: PMC3715974_01_IJMPO-34-24-g001.jpg
case_images: F1
case_images: PET-CT revealed no change in the status of left inguinal lymphadenopathy with persistent SUV max of 4.0; however, right-sided inguinal metastasis disappeared after biochemotherapy [Figures 1 and 2]. Patient developed grade 3 peripheral neuropathy after 12 weeks; hence, paclitaxel was discontinued and patient is now continuing on weekly nimotuzumab and has completed 23 weeks of nimotuzumab till date.
case_images: Clinical response post 12 weeks of bio-chemotherapy with significant resolution of cutaneous nodules and scrotal edema
case_images: IJMPO-34-24-g002.jpg
case_images: PMC3715974_01_IJMPO-34-24-g002.jpg
case_images: F2
case_images: PET-CT revealed no change in the status of left inguinal lymphadenopathy with persistent SUV max of 4.0; however, right-sided inguinal metastasis disappeared after biochemotherapy [Figures 1 and 2]. Patient developed grade 3 peripheral neuropathy after 12 weeks; hence, paclitaxel was discontinued and patient is now continuing on weekly nimotuzumab and has completed 23 weeks of nimotuzumab till date.